Therapeutic benefits by targeting CD47 are demonstrated in a series of pre-clinical and clinical studies in an array of human cancers34–37 including GBM treated with radiation and anti-CD47 antibody38, and CD47 is overexpressed in radioresistant breast cancer cells37. This evidence concerns the gene CD47 and breast cancer.